Precision fermentation is quietly becoming a supply chain strategy for biotech, not just a food tech story
DDDr. Dereck Mush, MD, MBA
Jul 1
HexemBio
Synthetic yolk sac platform that rejuvenates aged blood stem cells for transplant.
What they do
HexemBio is a synthetic biology company whose Synthetic Human Yolk Sac microenvironment platform rejuvenates aged autologous hematopoietic stem cells for bone marrow transplantation. The company has raised $15.5M from investors including Draper Associates, Boost VC and Happiness Capital.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Synthetic biology
- Product type
- Platform software
- Stage
- Seed
- Headquarters
- San Francisco, CA
- Region
- North America
- Founded
- Not disclosed
- Total funding
- $16M raised
Notable investors: Draper Associates, Boost VC, Happiness Capital.
Also in Pharma & Drug Discovery
Related on The Signal
AI is moving upstream, from molecule design into disease target identification itself
DDDr. Dereck Mush, MD, MBA
Mar 18The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
DDDr. Dereck Mush, MD, MBA
Jul 16
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
DDDr. Dereck Mush, MD, MBA
Jun 5